Company Updates

Aclarion (ACON) names Gregory Gould chief financial officer

ACON

Aclarion, Inc. (Nasdaq: ACON) appointed Gregory A. Gould as chief financial officer on September 2, 2025, replacing John Lorbiecki, who had given notice of his retirement in June 2025.

Investor Chat

Scorecard

ACON
Investor Impact: 4.5/10, ModerateHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
ModerateHigh evidence
Investment Attractiveness: 5.3/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

By the aibio.space news desk

A federal building and U.S. courthouse
A federal building and U.S. courthouse. Photo: United States District Court for the Eastern District of Missouri, Public domain, via Wikimedia Commons. The picture shows the field, not the companies named.

Aclarion, Inc. (Nasdaq: ACON) appointed Gregory A. Gould as chief financial officer on September 2, 2025. The company disclosed the appointment in a Form 8-K filed on September 3, 2025. Gould takes over from John Lorbiecki, who had told the company in June 2025 that he would retire from the role. The employment agreement is effective as of September 1, 2025.

Why is this important: A new chief financial officer arrives at a company that has raised money several times in the past year and has to report on its own cash and reporting controls. The appointment ends a search that began in June 2025. For shareholders, the change matters most for the quality of the numbers and the pace of financing. The filing says Gould will receive an annual base salary of $262,500 and a bonus of up to 50% of salary.

Brent Ness, the chief executive, is the company's chief operating decision maker in its financial statements. In our view, the appointment fills a seat the company had left open since June. The company's last quarterly report before the change described its disclosure controls as not effective, and a new finance chief inherits that problem along with the job. We think the board must show, in the next filings, that the new CFO has fixed the reporting process rather than inherited it.

The new CFO and his terms

The board appointed Gould on September 2, 2025. The 8-K describes him as a senior finance executive with more than two decades of experience in chief financial officer roles, at companies in the biopharmaceutical and wellness sectors. He is a Certified Public Accountant. The filing says he was chief financial officer of Nanos Health LLC, a pre-revenue pharmaceutical startup that works on drug delivery, from January 2023.

The employment agreement sets an annual base salary of $262,500, subject to annual adjustment by the board or compensation committee. Gould is eligible for an annual bonus of up to 50% of base salary, at the discretion of the board or the committee. The filing describes further terms in the agreement, which is summarized in the 8-K.

What the June notice said

On June 16, 2025, Lorbiecki notified the company that he intended to retire as chief financial officer. The company's June 20, 2025 filing says it began a search for his replacement and expected to appoint a new CFO before the end of the third quarter of 2025. Lorbiecki stayed on in a non-CFO role through October 1, 2025 to hand over the work. The June filing says he joined as CFO in October 2021, before the company's April 2022 initial public offering, and that his decision to retire did not result from any disagreement or difference of opinion with the company.

The appointment met the June timetable, which pointed to the end of the third quarter, and the board named the successor on September 2, 2025.

The cash and business context

The interim report for the quarter ended June 30, 2025, the latest periodic report before the appointment, reports cash, cash equivalents and restricted cash of $12,850,657, of which $25,000 is restricted. The company says the cash will fund its operating expenses and capital expenditures into the third quarter of 2026. Its six-month cash flow statement shows $14,554,545 from a public offering of common stock and warrants and $5,167,927 from registered direct offerings.

The company's revenue comes from Nociscan reports, which it delivers to clients for a fee. The second-quarter report says the company started The Clarity Trial, a post-market clinical study, and enrolled its first patient in June 2025. The filings name no ClinicalTrials.gov registration for that trial, so this article cites none.

The next dated item is the company's next quarterly report, which the 8-K did not date. The record names no further officer change.

The appointment is described in the Form 8-K filed September 3, 2025. The June notice is in the Form 8-K filed June 20, 2025, and the latest interim figures before the change are in the Form 10-Q for the quarter ended June 30, 2025.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.